The FDA has approved the first at-home, nonprescription test for chlamydia, gonorrhea, and trichomoniasis in women. The Visby ...

The US Food and Drug Administration has approved a single-use at-home test which can detect three STIs in women. Read on to ...

The FDA has granted Fast Track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection.

Jean-François Toussaint, Sanofi's global head of vaccines R&D, speaking at a conference at the company's site in Lyon last ...

Visby Medical’s at-home diagnostic, which can be purchased without a prescription, tests for chlamydia, gonorrhea and trichomoniasis.

Caused by the bacterium Chlamydia trachomatis, chlamydia is a common bacterial infection of the reproductive tract that can lead to infertility and pregnancy complications. The vaccine candidate ...

The US Food and Drug Administration (FDA) granted marketing authorization to Visby Medical for the Visby Medical Women’s Sexual Health Test. This is the first diagnostic test for chlamydia, gonorrhoea ...

Chlamydia vaccine candidate granted fast track designation by the US FDAChlamydia infection can contribute to pelvic inflammatory diseases in ...

The U.S. Food and Drug Administration granted marketing authorization for the first home-based, nonprescription diagnostic test for chlamydia, gonorrhea, and trichomoniasis in women, the agency ...

Sanofi’s chlamydia vaccine candidate was designed to protect against primary genital tract infection and reinfection by the bacterium Chlamydia trachomatis. The Food and Drug Administration (FDA ...

Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to pregnancy complications or infertility A phase 1/2 clinical study evaluating the immunogenicity and ...

The US Food and Drug Administration (FDA) has granted marketing authorization for the first at-home test to diagnose ...